Logo
x

Search

Subscribe Now

Cabometyx

Exelixis Reports the US FDA’s Approval of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors (NETs)

Exelixis Reports the US FDA’s Approval of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors (NETs)

  • March 27, 2025
Exelixis Presents 5-year Follow-Up Data from P-III (CheckMate -9ER) of Cabometyx + Opdivo in Renal Cell Carcinoma Patients at ASCO GU 2025

Exelixis Presents 5-year Follow-Up Data from P-III (CheckMate -9ER) of Cabometyx + Opdivo in Renal Cell Carcinoma Patients at ASCO...

  • February 18, 2025
Exelixis Reports the US FDA’s sNDA Acceptance of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors

Exelixis Reports the US FDA’s sNDA Acceptance of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors

  • August 7, 2024
Ipsen Reports Collaboration Expansion with Exelixis to Develop Cabometyx for Treating Neuroendocrine Tumors

Ipsen Reports Collaboration Expansion with Exelixis to Develop Cabometyx for Treating Neuroendocrine Tumors

  • July 2, 2024
BMS Reports 4-Year Follow-Up Data for Opdivo with Cabometyx in P-III Trial to Treat Advanced Renal Cell Carcinoma (RCC)

BMS Reports 4-Year Follow-Up Data for Opdivo with Cabometyx in P-III Trial to Treat Advanced Renal Cell Carcinoma (RCC)

  • January 23, 2024
BMS and Exelixis Report P-III Trial (CheckMate -9ER) Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) as 1L Treatment of Advanced Renal Cell Carcinoma

BMS and Exelixis Report P-III Trial (CheckMate -9ER) Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) as 1L Treatment of A...

  • February 14, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.